Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$3.75 -4.1%	$5.41	$3.39 ▼ $16.00	$40.61M	0.87	53,951 shs	29,521 shs
CTMX CytomX Therapeutics	$2.23 +4.7%	$0.97	$0.40 ▼ $2.55	$179.79M	1.11	2.12 million shs	3.08 million shs
ELDN Eledon Pharmaceuticals	$3.05 +1.0%	$3.12	$2.30 ▼ $5.54	$182.64M	0.08	272,701 shs	175,430 shs
TLSA Tiziana Life Sciences	$1.58 +15.3%	$1.20	$0.63 ▼ $1.91	$184.62M	0.29	475,497 shs	866,786 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	-4.09%	-4.09%	-24.24%	-55.57%	-65.25%
CTMX CytomX Therapeutics	+4.69%	+9.85%	+205.40%	+185.90%	+18.62%
ELDN Eledon Pharmaceuticals	+0.99%	+6.27%	-9.23%	-28.90%	+2.01%
TLSA Tiziana Life Sciences	+15.33%	+16.18%	+20.61%	+92.71%	+95.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTX Avalo Therapeutics	3.3892 of 5 stars	4.4	5.0	0.0	0.0	1.7	1.3
CTMX CytomX Therapeutics	4.2216 of 5 stars	3.5	1.0	4.7	3.0	2.5	1.3
ELDN Eledon Pharmaceuticals	1.9718 of 5 stars	3.5	2.0	0.0	2.9	1.7	0.0
TLSA Tiziana Life Sciences	0.6168 of 5 stars	0.0	5.0	0.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.83	Moderate Buy	$33.00	780.00% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	139.16% Upside
ELDN Eledon Pharmaceuticals	3.00	Buy	$12.50	309.84% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AVTX, TLSA, ELDN, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
3/25/2025	AVTX Avalo Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform ➝ Buy	$23.00
3/25/2025	AVTX Avalo Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
3/20/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/20/2025	AVTX Avalo Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$18.00
3/7/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/7/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
2/28/2025	AVTX Avalo Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$48.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$441K	92.07	N/A	N/A	$9.11 per share	0.41
CTMX CytomX Therapeutics	$147.56M	1.22	N/A	N/A	($0.71) per share	-3.14
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$0.30 per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$31.54M	N/A	0.00	N/A	N/A	N/A	-442.16%	122.99%	8/11/2025 (Estimated)
CTMX CytomX Therapeutics	-$570K	$0.48	13.12	N/A	N/A	10.96%	-41.47%	8.11%	N/A
ELDN Eledon Pharmaceuticals	-$116.54M	-$2.10	N/A	N/A	N/A	N/A	-189.99%	-28.17%	N/A
TLSA Tiziana Life Sciences	-$17.69M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest AVTX, TLSA, ELDN, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELDN Eledon Pharmaceuticals	-$0.28	-$0.08	+$0.20	-$0.08	N/A	N/A
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
3/20/2025	Q4 2024	ELDN Eledon Pharmaceuticals	-$0.32	-$0.64	-$0.32	-$0.64	N/A	N/A
3/6/2025	Q4 2024	CTMX CytomX Therapeutics	-$0.23	$0.22	+$0.45	$0.22	$13.53 million	$38.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	1.42	1.42
CTMX CytomX Therapeutics	N/A	1.04	1.04
ELDN Eledon Pharmaceuticals	N/A	6.53	6.53
TLSA Tiziana Life Sciences	N/A	0.85	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
CTMX CytomX Therapeutics	67.77%
ELDN Eledon Pharmaceuticals	56.77%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	3.03%
CTMX CytomX Therapeutics	7.00%
ELDN Eledon Pharmaceuticals	12.30%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.37 million	Not Optionable
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.75 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	63.43 million	Optionable

AVTX, TLSA, ELDN, and CTMX Headlines

Recent News About These Companies

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23 at 10:59 AM | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23 at 7:00 AM | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 12, 2025 | globenewswire.com

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab

May 9, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025 | globenewswire.com

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

May 8, 2025 | pmlive.com

Tiziana shares surge 21% on promising multiple sclerosis data

May 6, 2025 | proactiveinvestors.com

Tiziana reports encouraging results for nasal MS drug in early study

May 6, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025 | globenewswire.com

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

April 30, 2025 | insidermonkey.com

Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts

April 23, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

April 23, 2025 | globenewswire.com

Tiziana Life announces dosing at JHU, part of Phase 2 trial of foralumab

April 3, 2025 | markets.businessinsider.com

Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins

April 2, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

April 2, 2025 | globenewswire.com

Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS

March 25, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

March 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX, TLSA, ELDN, and CTMX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$3.75 -0.16 (-4.09%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$3.94 +0.19 (+5.07%)

As of 05/23/2025 07:14 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

CytomX Therapeutics NASDAQ:CTMX

$2.23 +0.10 (+4.69%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$2.22 0.00 (-0.22%)

As of 05/23/2025 07:49 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Eledon Pharmaceuticals NASDAQ:ELDN

$3.05 +0.03 (+0.99%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$3.05 0.00 (0.00%)

As of 05/23/2025 04:04 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Tiziana Life Sciences NASDAQ:TLSA

$1.58 +0.21 (+15.33%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.56 -0.02 (-1.27%)

As of 05/23/2025 07:55 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time